1383TiP - Blood First Line Ready Screening Trial (B-F1RST) and Blood First Assay Screening Trial (BFAST) Enable Clinical Development of Novel Blood-Based Bio...

Date 09 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancer in Adolescents
Non-Small-Cell Lung Cancer, Locally Advanced
Non-Small-Cell Lung Cancer, Metastatic
Lung and other Thoracic Tumours
Translational Research
Presenter Tony S.K. Mok
Citation Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380
Authors T.S.K. Mok1, S. Gadgeel2, E.S. Kim3, V. Velcheti4, S. Hu5, T. Riehl6, E. Schleifman7, S.M. Paul8, S. Mocci9, D.S. Shames7, S. Phan10, C. Yun11, M. Mathisen12, M. Kowanetz7, U. Sweere13, M.A. Socinski14
  • 1Clinical Oncology, Chinese University of Hong Kong, 000 - Hong Kong/CN
  • 2Medical Oncoloy, University of Michigan, Ann Arbor/US
  • 3Medical Oncoloy, Levine Cancer Institute, Carolinas Health Care System, Charlotte/US
  • 4Hematology And Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland/US
  • 5Biostatistics, Genentech, Inc., South San Francisco/US
  • 6Product Development Clinical (oncology), Genentech, South San Francisco/US
  • 7Oncology Biology Development, Genentech, South San Francisco/US
  • 8Oncology Biomarker Development, Genentech, South San Francisco/US
  • 9Product Development Oncology, Genentech, Inc., South San Francisco/US
  • 10Usma, Genentech, South San Francisco/US
  • 11Usma, Genentech, Inc., South San Francisco/US
  • 12Oncology Biomarker Development, Genentech, Inc., South San Francisco/US
  • 13Pdg, F. Hoffmann-La Roche Ltd, Basel/CH
  • 14Thoracic Oncology Program, Florida Hospital Cancer Institute, Orlando/US



Several clinical trials have confirmed the safety and efficacy of atezolizumab (atezo; anti–PD-L1) monotherapy in advanced NSCLC, including in PD-L1–selected 1L patients (pts). Independent of PD-L1 status, high TMB is associated with atezo efficacy. Alectinib is a potent, selective ALK/RET kinase inhibitor currently approved for NSCLC pts previously treated with crizotinib and is expected to have activity in 1L NSCLC pts with ALK or RET alterations. Currently, molecular diagnostics require tumor biopsies which can be difficult to obtain. Here we present trials in progress that aim to clinically evaluate and prospectively validate novel blood-based diagnostic assays that measure TMB in the blood (bTMB) and somatic mutations (e.g., ALK/RET), and to determine the efficacy and safety of 1L atezo or alectinib in NSCLC pts.

Trial design

B-F1RST (NCT02848651) is a single-arm study to evaluate the efficacy and safety of atezo and the association between bTMB and efficacy in biomarker-unselected pts. BFAST is a screening and interventional umbrella trial for pts selected based on bTMB or somatic mutations. Eligible pts must have previously untreated, stage IIIB-IVB NSCLC of any histology and measurable disease per RECIST v1.1. Pts will continue treatment until disease progression (all arms) or loss of clinical benefit (atezo only). In B-F1RST, mandatory blood samples will be prospectively collected and retrospectively tested for bTMB. In BFAST, pre-enrollment screening will identify pts who harbor oncogenic somatic mutations (ALK/RET) or are bTMB + (above a pre-specified cutoff); pts will be assigned to the appropriate cohort based on screening results. Study treatments and key endpoints are shown in the table. Additional BFAST cohorts may be added in the future to address other somatic mutations.Table:

1383TiP B-F1RST and BFAST Study Details

StudyTreatmentPlanned Enrollment, nPrimary EndpointsKey Secondary Endpoints
B-F1RST Phase IIAtezo 1200 mg IV q3w150ORR per RECIST v1.1 (INV-assessed) for the efficacy objective Relationship between PFS per RECIST v1.1 and various bTMB quantiles for the biomarker objectivePFS and DOR per RECIST v1.1 (INV-assessed) OS
Cohort A ALK+Alectinib 600 mg PO bid78ORR per RECIST v1.1 (INV-assessed)DOR, CBR and PFS per RECIST v1.1 (INV-assessed) ORR, DOR, CBR and PFS per RECIST v1.1 (IRF-assessed) OS
Cohort B RET+Alectinib 900 mg & 1200 mg dose escalation52-62ORR per RECIST v1.1 (INV-assessed)DOR, CBR and PFS per RECIST v1.1 (INV-assessed) ORR, DOR, CBR and PFS per RECIST v1.1 (IRF-assessed) OS
Cohort C bTMB+Atezo 1200 mg IV q3w or platinum-based chemotherapya440 (R, 1:1)PFS per RECIST v1.1 (INV-assessed)OS PFS, ORR and DOR per RECIST v1.1 (IRF-assessed) ORR and DOR per RECIST v1.1 (INV-assessed) 6- and 12-month PFS rates

Cisplatin or carboplatin + pemetrexed for non-squamous histology, and cisplatin or carboplatin + gemcitabine for squamous histology. Administered per standard of care. INV, investigator; IRF, independent review facility; R, randomized;


TMB, blood Tumor Mutational Burden.

Clinical trial identification

NCT02848651, B-FAST NCT number available on poster

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.


F. Hoffmann-La Roche Ltd.


T.S.K. Mok: Spt: AZ, BI, PFE, NV, SFJ, ROG, MSD, CLVS, BMS, Eisai, Taiho ROG/GNE, LLY, NV; Stock Sanomics AB: AZ, ROG/GNE, PFE, LLY, BI, CLVS, MSD, NV, SFJ, ACEA Bio, VRTX, BMS, GeneDecode, OGX, CELG, RXDX Bod: IASLC, CLCRF, CSCO, HKCTS. S. Gadgeel: Speaker\'s bureau‐ Astra‐Zeneca, Genentech/Roche Advisory Boards‐ Astra‐Zeneca, Ariad, Pfizer, Bristol Myers‐ Squibb and Genentech/Roche. E.S. Kim: Consulting or advisory role: AstraZeneca, Celgene, BI, Eli Lily. V. Velcheti: Consulting/advisory role: Genentech, BMS, Merck, AstraZeneca, Foundation Medicine, Genoptix, Amgen. S. Hu, D.S. Shames: Genentech employee and Roche stock. T. Riehl, E. Schleifman, S. Mocci, S. Phan, M. Mathisen: Genentech employee. S.M. Paul: Genentech employee, Roche Stock, Travel, Accommodations, Expenses from Genentech. C. Yun: Employee of Genentech, Roche stock, Research funding from Genentech. M. Kowanetz: Genentech employee & Roche stock. U. Sweere: Roche employee. M.A. Socinski: Honoraria: Genentech Speakers Bureau: Genentech Research Funding: Genentech.